Skip to main content

Viral vectored transmission blocking vaccines against Plasmodium falciparum


Transmission blocking vaccines (TBVs) target sexual develop¬ment of the parasite within the mosquito and aim to prevent transmission of malaria from one individual to another. Antibodies raised against Pfs48/45, Pfs230 Region C, PfHAP2, and Anopheles gambiae Alanyl Aminopeptidase N1 (AgAPN1) proteins reduce transmission i.e. have transmission blocking activity [15]. Recombinant simian Adenovirus (AdC63 serotype) and Modified Vaccinia Ankara (MVA) viral vectors have been shown to induce high antibody titres to asexual parasite antigens in animal studies [6].

Materials and methods

Protein sequences for each of the antigens were codon optimised for expression in humans and cloned into shuttle vectors, which were then recombined with the parental virus and purified to obtain virus expressing the antigen of interest. Mice were vaccinated with AdC63 (i.m.), sera was taken after 2 weeks, and will be followed by an MVA boost (i.d.) eight weeks after the prime. Antibodies were assayed by a standardised ELISA, and transmission blocking activity assessed using a standardised membrane feeding assay (SMFA).


Induction of high antibody tires using this vaccine platform could be used together with other control measures to achieve elimination and/or eradication of the disease at a local or national level.


  1. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, Pandey A, Jacobs-Lorena M: Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc Natl Acad Sci USA. 2007, 104: 13461-6. 10.1073/pnas.0702239104.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Chowdhury DR, Angov E, Kariuki T, Kumar N: A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One. 2009, 4: e6352-10.1371/journal.pone.0006352.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Bustamante PJ, Woodruff DC, Oh J, Keister DB, Muratova O, Williamson KC: Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Parasite Immunol. 2000, 22: 373-80. 10.1046/j.1365-3024.2000.00315.x.

    Article  CAS  PubMed  Google Scholar 

  4. Blagborough AM, Sinden RE: Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro. Vaccine. 2009, 27: 5187-94. 10.1016/j.vaccine.2009.06.069.

    Article  CAS  PubMed  Google Scholar 

  5. Vermeulen AN, Ponnudurai T, Beckers PJ, Verhave JP, Smits MA, Meuwissen JH: Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med. 1985, 162: 1460-76. 10.1084/jem.162.5.1460.

    Article  CAS  PubMed  Google Scholar 

  6. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F, Hill AV: Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008, 14: 819-821. 10.1038/nm.1850.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Kapulu, M.C., Biswas, S., Blagborough, A. et al. Viral vectored transmission blocking vaccines against Plasmodium falciparum. Malar J 9 (Suppl 2), O22 (2010).

Download citation

  • Published:

  • DOI: